- Home
- MDWD vs VOR Comparison
MDWD vs VOR Comparison
Compare MDWD & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDWD
- VOR
- Stock Information
- Founded
- MDWD 2000
- VOR 2015
- Country
- MDWD Israel
- VOR United States
- Employees
- MDWD N/A
- VOR N/A
- Industry
- MDWD Medicinal Chemicals and Botanical Products
- VOR Biotechnology: Pharmaceutical Preparations
- Sector
- MDWD Health Care
- VOR Health Care
- Exchange
- MDWD Nasdaq
- VOR Nasdaq
- Market Cap
- MDWD 184.8M
- VOR 161.9M
- IPO Year
- MDWD 2014
- VOR 2021
- Fundamental
- Price
- MDWD $19.45
- VOR $1.39
- Analyst Decision
- MDWD Strong Buy
- VOR Strong Buy
- Analyst Count
- MDWD 1
- VOR 7
- Target Price
- MDWD $25.00
- VOR $11.36
- AVG Volume (30 Days)
- MDWD 78.0K
- VOR 808.2K
- Earning Date
- MDWD 03-20-2025
- VOR 03-19-2025
- Dividend Yield
- MDWD N/A
- VOR N/A
- EPS Growth
- MDWD N/A
- VOR N/A
- EPS
- MDWD N/A
- VOR N/A
- Revenue
- MDWD $19,720,000.00
- VOR N/A
- Revenue This Year
- MDWD $10.15
- VOR N/A
- Revenue Next Year
- MDWD $25.62
- VOR N/A
- P/E Ratio
- MDWD N/A
- VOR N/A
- Revenue Growth
- MDWD N/A
- VOR N/A
- 52 Week Low
- MDWD $11.04
- VOR $0.63
- 52 Week High
- MDWD $24.00
- VOR $2.43
- Technical
- Relative Strength Index (RSI)
- MDWD 55.03
- VOR 54.50
- Support Level
- MDWD $19.59
- VOR $1.29
- Resistance Level
- MDWD $20.62
- VOR $1.48
- Average True Range (ATR)
- MDWD 0.83
- VOR 0.14
- MACD
- MDWD 0.02
- VOR -0.02
- Stochastic Oscillator
- MDWD 54.60
- VOR 45.95
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.